4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $38.56.

A number of brokerages recently weighed in on FDMT. Leerink Partners lowered their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, January 13th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $40.00 to $15.00 in a report on Monday, January 13th. Chardan Capital reiterated a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Saturday, January 18th.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently made changes to their positions in FDMT. State Street Corp lifted its holdings in 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after purchasing an additional 37,232 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after acquiring an additional 1,087,147 shares during the last quarter. Novo Holdings A S grew its stake in 4D Molecular Therapeutics by 7.1% during the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after acquiring an additional 100,000 shares in the last quarter. Redmile Group LLC increased its holdings in 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after acquiring an additional 188,655 shares during the last quarter. Finally, Braidwell LP lifted its stake in 4D Molecular Therapeutics by 231.7% in the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $4.66 on Friday. 4D Molecular Therapeutics has a 1 year low of $4.43 and a 1 year high of $36.25. The stock’s fifty day moving average price is $6.31 and its 200-day moving average price is $10.91. The company has a market cap of $215.43 million, a P/E ratio of -1.64 and a beta of 2.81.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.